Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10312093 | 0.91 | IGF1R (0.43) | IGF1RNTRK1 | |
| SCHEMBL16556861 | 0.89 | IGF1R (0.42) | IGF1RNTRK1 | |
| SCHEMBL10312134 | 0.88 | KMT2A (0.37) | IGF1RNTRK1 | |
| SCHEMBL10312150 | 0.86 | IGF1R (0.48) | IGF1RNTRK1 | |
| SCHEMBL10312188 | 0.83 | JAK2 (0.41) | NTRK1 | |
| SCHEMBL10312193 | 0.83 | AURKA (0.41) | IGF1RNTRK1 | |
| SCHEMBL16556865 | 0.83 | IGF1R (0.41) | IGF1RNTRK1 | |
| SCHEMBL10312072 | 0.81 | IDH2 (0.41) | IGF1RNTRK1 | |
| SCHEMBL10312200 | 0.80 | GRK6 (0.35) | IGF1RNTRK1 | |
| SCHEMBL10312090 | 0.79 | IDH2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178758-A1 | STYRYL-TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | STK25, STK35, SGK2 | IGF1R 1148/4885NTRK1 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.